Integrated Injectable Therapies in the Modulation of Chronic Inflammation in Obesity, Cancer, and Type 2 Diabetes

Chronic inflammation is a central factor in the pathogenesis of obesity, cancer, and type 2 diabetes (T2DM). This article explores an integrated therapeutic strategy, administered via injection, that combines dimethyl sulfoxide (DMSO), coenzyme Q10 (CoQ10), alpha-lipoic acid (ALA), curcumin, Glutathione (GSH), and miR-146a mimetics. Injectable administration optimizes the bioavailability and tissue targeting of these agents, which act synergistically through anti-inflammatory, antioxidant, and metabolic modulating mechanisms. The main focus is on the role of miR-146a in regulating the IRAK1 and TRAF6 signaling pathway, crucial for immunometabolic homeostasis. This multidimensional approach has the potential to modulate chronic inflammation, optimize mitochondrial function, and restore metabolic balance, representing a new frontier in the treatment of chronic inflammatory diseases.